Targeting the nucleolus for cancer-specific activation of p53

Drug Discovery Today

Volumn 19, Issue 3, 2014, Pages 259-265

  Drygin, Denis ^a   O'Brien, Sean E ^b   Hannan, Ross D ^c,d   McArthur, Grant A ^c,d   Von Hoff, Daniel D ^e  

^a Cylene Pharmaceuticals   (United States)

^b Senhwa Biosciences   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RIBOSOME RNA; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; CX 5461; NAPHTHYRIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BIOGENESIS; CANCER THERAPY; CELL CYCLE CHECKPOINT; CELL FUNCTION; CELL STRESS; CLINICAL DEVELOPMENT PLAN; DNA DAMAGE; GENOTOXICITY; HUMAN; NUCLEOLUS; PROTEIN SYNTHESIS; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; CELL NUCLEOLUS; DNA DAMAGE; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NAPHTHYRIDINES; NEOPLASMS; RNA, RIBOSOMAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896405456     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.08.012     Document Type: Review

References (63)

1. F. Fontana Traite sur le venin de la viper, sur les poisons americains, sur le laurier-cerise et sur quelques autres poisons vegetaux 1781 Gibelin Florence
2. G. Pianese Beitrag zur histologie und aetiologie der carcinoma. Histologische und experimentelle untersuchungen Beitr. Pathol. Anat. Allgem. Pathol. 142 1896 1 193
3. C. Goodpasture, and S.E. Bloom Visualization of nucleolar organizer regions in mammalian chromosomes using silver staining Chromosoma 53 1975 37 50
4. M. Aubele et al. Guidelines of AgNOR quantitation. Committee on AgNOR Quantitation within the European Society of Pathology Zentralbl. Pathol. 140 1994 107 108
5. D. Treré AgNOR staining and quantification Micron 31 2000 127 131
6. A. Pich et al. Prognostic relevance of AgNORs in tumor pathology Micron 31 2000 133 141
7. L.B. Maggi, and J.D. Weber Nucleolar adaptation in human cancer Cancer Invest. 23 2005 599 608 (Pubitemid 43286662)
8. F.M. Boisvert et al. The multifunctional nucleolus Nat. Rev. Mol. Cell. Biol. 8 2007 574 585
9. J.S. Andersen et al. Nucleolar proteome dynamics Nature 433 2005 77 83 (Pubitemid 40101146)
10. J.M. Wong et al. Subnuclear shuttling of human telomerase induced by transformation and DNA damage Nat. Cell Biol. 4 2002 731 736 (Pubitemid 34993712)
11. M.O. Olson Sensing cellular stress: another new function for the nucleolus Sci. STKE 224 2004 pe10
12. D. Treré et al. Nucleolar size and activity are related to pRb and p53 status in human breast cancer J. Histochem. Cytochem. 52 2004 1601 1607 (Pubitemid 39603258)
13. D. Ruggero, and P.P. Pandolfi Does the ribosome translate cancer? Nat. Rev. Cancer 3 2003 179 192 (Pubitemid 37328870)
14. L. Montanaro et al. Nucleolus, ribosomes, and cancer Am. J. Pathol. 173 2008 301 310
15. N. Shenoy et al. Alterations in the ribosomal machinery in cancer and hematologic disorders J. Hematol. Oncol. 5 2012 32
16. L. Montanaro, and P.P. Padolfi Initiation of mRNA translation in oncogenesis: the role of eIF4E Cell Cycle 3 2004 1387 1389 (Pubitemid 40310673)
17. D. Ruggero et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis Nat. Med. 10 2004 484 486 (Pubitemid 38667906)
18. M. Barna et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency Nature 465 2008 971 975
19. J. Cortes et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors Am. J. Hematol. 88 2013 350 354
20. S. Chédin et al. Is ribosome synthesis controlled by pol I transcription? Cell Cycle 6 2007 11 15 (Pubitemid 46173873)
21. I. Grummt, and G. Längst Epigenetic control of RNA polymerase I transcription in mammalian cells Biochim. Biophys. Acta 1829 2013 393 404
22. A. Murayama Epigenetic control of rDNA loci in response to intracellular energy status Cell 133 2008 627 639 (Pubitemid 351636301)
23. E. Sanij, and R.D. Hannan The role of UBF in regulating the structure and dynamics of transcriptionally active rDNA chromatin Epigenetics 4 2009 374 382
24. I. Grummt Wisely chosen paths - regulation of rRNA synthesis FEBS J. 277 2010 4626 4639
25. S.J. Goodfellow, and J.C. Zomerdijk Basic mechanisms in RNA polymerase I transcription of the ribosomal RNA genes Subcell. Biochem. 61 2012 211 236
26. T. Moss et al. A housekeeper with power of attorney: the rRNA genes in ribosome biogenesis Cell. Mol. Life Sci. 64 2007 29 49 (Pubitemid 46159444)
27. J. Zhao et al. ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth Mol. Cell 11 2003 405 413 (Pubitemid 36293834)
28. K.M. Hannan et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF Mol. Cell Biol. 23 2003 8862 8877 (Pubitemid 37433385)
29. V. Stefanovsky et al. Growth factor signaling regulates elongation of RNA polymerase I transcription in mammals via UBF phosphorylation and r-chromatin remodeling Mol. Cell 21 2006 629 639 (Pubitemid 43290730)
30. J.C. Chan et al. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer Sci. Signal. 4 2011 ra56
31. C. Mayer et al. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability Genes Dev. 18 2004 423 434 (Pubitemid 38316349)
32. D. Drygin et al. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer Annu. Rev. Pharmacol. 50 2010 131 156
33. D. Williamson Nascent pre-rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma Genes Chromosomes Cancer 45 2006 839 845 (Pubitemid 44182442)
34. G. Poortinga et al. MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation EMBO J. 23 2004 3325 3335 (Pubitemid 39209156)
35. G. Poortinga et al. c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation Nucleic Acids Res. 39 2011 3267 3281
36. K. Murano et al. Transcription regulation of the rRNA gene by a multifunctional nucleolar protein, B23/nucleophosmin, through its histone chaperone activity Mol. Cell Biol. 28 2008 3114 3126 (Pubitemid 351657078)
37. R.S. Savkur, and M.O. Olson Preferential cleavage in pre-ribosomal RNA byprotein B23 endoribonuclease Nucleic Acids Res. 26 1998 4508 4515 (Pubitemid 28442146)
38. L.Y. Li et al. Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes Cancer Res. 71 2011 4269 4279
39. W. Zhai et al. SV40 large T antigen binds to the TBP-TAF(I) complex SL1 and coactivates ribosomal RNA transcription Genes Dev. 11 1997 1605 1617 (Pubitemid 27274404)
40. K.M. Hannan et al. Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1 Oncogene 19 2000 4988 4999
41. W. Zhai, and L. Comai Repression of RNA polymerase I transcription by the tumor suppressor p53 Mol. Cell Biol. 20 2000 5930 5938 (Pubitemid 30613042)
42. C. Zhang et al. PTEN represses RNA polymerase I transcription by disrupting the SL1 complex Mol. Cell Biol. 25 2005 6899 6911 (Pubitemid 41105891)
43. O. Ayrault Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation Oncogene 25 2006 7577 7586 (Pubitemid 44924471)
44. F. Lessard et al. The ARF tumor suppressor controls ribosome biogenesis by regulating the RNA polymerase I transcription factor TTF-I Mol. Cell 38 2010 539 550
45. K.M. Hannan et al. Dysregulation of RNA polymerase I transcription during disease Biochim. Biophys. Acta 1829 2013 342 360
46. C.J. Brown et al. Awakening guardian angels: drugging the p53 pathway Nat. Rev. Cancer 9 2009 862 873
47. N. Hijiya et al. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues Cancer 115 2009 23 35
48. C.F. Cheok et al. Translating p53 into the clinic Nat. Rev. Clin. Oncol. 8 2011 25 37
49. C.J. Brown et al. Reactivation of p53: from peptides to small molecules Trends Pharmacol. Sci. 32 2011 53 62
50. Andreef, M. et al. (2012) Results of the Phase 1 trial of RG7112, a small-molecule MDM2 antagonist, in acute leukemia. ASH abstract. Available at: https://ash.confex.com/ash/2012/webprogram/Paper46805.html
51. Patnaik, A. (2013) Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. AACR abstract. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID= 3086&sKey=98112b22-5e11-4628-9e32-3905cc0aa268&cKey=8c9c1f8a-493f-44f5- af94-e9eae776aeed&mKey=%7B9B2D28E7-24A0-466F-A3C9-07C21F6E9BC9%7D
52. D. Ruggero Revisiting the nucleolus: from marker to dynamic integrator of cancer signaling Sci. Signal. 5 2012 pe38
53. C. Deisenroth, and Y. Zhang Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway Oncogene 29 2010 4253 4260
54. X. Zhou et al. Scission of the p53-MDM2 loop by ribosomal proteins Genes Cancer 3 2012 298 310
55. J. Fetherston et al. Processing of the external transcribed spacer of murine rRNA and site of action of actinomycin D Nucleic Acids Res. 12 1984 7187 7198
56. D.K. Treiber et al. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor) Proc. Natl. Acad. Sci. U. S. A. 91 1994 5672 5676 (Pubitemid 24174390)
57. P. Jordan, and M. Carmo-Fonseca Cisplatin inhibits synthesis of ribosomal RNA in vivo Nucleic Acids Res. 26 1998 2831 2836 (Pubitemid 28297513)
58. K. Ghoshal, and S.T. Jacob An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug Biochem. Pharmacol. 53 1997 1569 1575 (Pubitemid 27356085)
59. K. Burker et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels J. Biol. Chem. 285 2010 12416 12425
60. D. Drygin et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth Cancer Res. 71 2011 1418 1430
61. M.J. Bywater et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53 Cancer Cell 22 2012 51 65
62. J. Zuber et al. Mouse models of human AML accurately predict chemotherapy response Genes Dev. 23 2009 877 889
63. Hein, N. (2011) Inhibition of RNA polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in MLL-rearranged acute myeloid leukemias. ASH abstract. Available at: https://ash.confex.com/ash/2011/webprogram/Paper42896.html